Everolimus mTOR inhibitor  

Certican - Afinitor - RAD001 - RAD 001 - 40-O-(2-hydroxyethyl)-rapamycin - SDZ-RAD - SDZ RAD      

Select             pdf
Trial Studied trt Control trt patientstagsROB Trial resultprogression or death (progression free survival PFS) death (overall survival)

advanced breast cancer (metastatic)  

BOLERO-2, 2011        NCTeverolimus + exemestaneexemestane alone HER-2 negative HR positive nsNAI failure previously treated with endocrine therapy Low risk of bias conclusive-57%-11%
TAMRAD , 2012      NCTeverolimus + tamoxifentamoxifen alone 1st line HER-2 negative HR positive postmenopausal previously treated with endocrine therapy Risk of bias suggesting-55%
BOLERO-3, 2014      NCTeverolimus + trastuzumab + vinorelbinetrastuzumab + vinorelbine alone HER-2 positive previously treated by taxanes trastuzumab failure Low risk of bias conclusive-22%

renal-cell carcinoma (advanced)  

RECORD-1, 2008      NCTeverolimusplacebosuggesting-70%-17%
RECORD 3, 2014      NCTeverolimussunitinib - 40%